The mechanism by which aplidine, a marine natural product in early clinical development as an anticancer agent, induces cell growth inhibition and apoptosis has been investigated in the human leukemia cell line MOLT-4. This cell line is characterized not only by the ability to secrete VEGF, but also for the presence on its surface of the VEGF receptor-1 (VEGFR-1). Previous studies from our laboratory concerned with evaluating early changes in gene expression induced by aplidine in MOLT-4 cells have shown that the drug decreases the expression of VEGFR-1 (Marchini et al. Proc Am Assoc Cancer Res 2000; 41: 833). Here, we report the ability of aplidine to block the VEGF/VEGFR-1 loop. We found that aplidine blocked VEGF secretion that was temporally followed by a decrease in both VEGF and VEGFR-1 production. Aplidine did not directly affect either VEGF transcription or stabilization of its mRNA. Transfection of MOLT-4 cells with an antisense VEGF cDNA construct, resulted in inhibition of colony formations. One clone, transfected with sense VEGF cDNA, secreting 8-10 times more VEGF than parental cells, was less sensitive to aplidineinduced cytotoxicity and apoptosis than control cells. Moreover, addition of VEGF in the medium decreased the activity of aplidine in MOLT-4 cells. These data demonstrate that aplidine inhibits the growth and induces apoptosis in MOLT-4 cells through the inhibition of VEGF secretion which blocks the VEGF/VEGFR-1 autocrine loop necessary for the growth of these cells.
Introduction
Aplidine, dehydrodidemnin B (see structure in Figure 1 ) is a new marine depsipeptide isolated from Aplidium albicans, shows strong antitumor activity against different human cancer cells growing in vitro and in vivo. [1] [2] [3] [4] [5] It has completed phase I trials and is under phase II development. [6] [7] [8] [9] Although its precise mechanism of action is still unknown, aplidine is able to induce rapid p53-independent apoptosis in different cancer cell lines growing in vitro. 10, 11 It has also been shown that the drug induces a cell cycle perturbation with a block of human leukemic MOLT-4 cells mainly in G1 phase of the cell cycle. 10, 11 Studies on changes in gene expression induced by aplidine in this cell line revealed a strong alteration of the pattern of gene expression at early times after treatment. 12 Among these changes is a clear and reproducible decrease in the expression of the VEGFR-1 (vascular endothelial growth factor-receptor 1, flt-1). 
Figure 1
Chemical structure of aplidine.
This receptor is a member of a family of receptors able to bind the angiogenic factor VEGF (vascular endothelial growth factor), and is normally present on the surface of vascular endothelial cells. [13] [14] [15] [16] [17] Increasing evidence suggests, however, that certain cancer cells of different origin, including leukemic cells, also express VEGF receptors on their surface. [18] [19] [20] [21] [22] [23] On the other hand, VEGF is secreted by virtually all cancer cells as a homodimeric glycoprotein which is able to bind VEGFR-1 and other components of the VEGF receptors family with high affinity. 14, 24 The simultaneous presence of a receptor and the ability to secrete the ligand for it, suggests the possible presence of an autocrine loop important for the growth of cancer cells expressing these receptors. In different experimental systems it has been shown that VEGF can act as an autocrine factor. [25] [26] [27] [28] [29] Furthermore, VEGF has been shown to act as a survival factor inhibiting apoptosis through the expression of antiapoptotic proteins. 17, 30, 31 In this study we present evidence of a strong effect of aplidine on the VEGF/VEGFR-1 autocrine loop regulating the growth of the human leukemic cell line MOLT-4. These findings indicate one of the mechanisms by which the drug is able to induce growth arrest and apoptosis in cancer cells thus providing a clinically relevant mechanistic insight.
Materials and methods

Cells, clones and treatment
The human leukemic cell line MOLT-4, derived from a patient suffering from T-lymphoblastic leukemia relapsed after multidrug chemotherapy, 32 was maintained in RPMI 1640 sup-plemented with 10% FCS. Exponentially growing cells were treated for 1 h with 0, 1, 5, 10 or 20 nM of aplidine. Cell counts were taken after 24, 48 and 72 h of incubation in drugfree medium after staining with erythrosin. Activity of aplidine in the presence of exogenous VEGF was tested by adding 10 ng/ml of recombinant human VEGF (R&D Systems, Minneapolis, MN, USA) every 24 h in the medium. These experiments were performed in low-serum concentration (1%), to minimize the effects of grow factors present in the serum. Human umbilical vein endothelial cells (HUVEC, kindly provided by Dr Breviario, Mario Negri Institute, Milan, Italy) were used as cells not secreting VEGF. Adherent cells were treated for 1 h with 5 or 20 nM aplidine and total mRNA was extracted 6 and 24 h after treatment using the SV Total RNA kit (Promega, Milan, Italy).
MOLT-4 cells were transfected with the human VEGF cDNA, both in sense and antisense orientation (kindly supplied by M Presta, University of Brescia, Italy) by electroporation. Seventy-two hours after transfection, cells were seeded in 96-well plates at the density of 0.5 cells/well in medium containing 500 g/ml of G418 used as selection antibiotic. The number of colonies formed were quantified after approximately 14 days. As a control, human ovarian cancer cells A2780 were transfected by calcium phosphate precipitation using the same constructs. This cell line was selected as a negative control because of the lack of expression of VEGF receptors and because it had already been successfully used in our laboratory in transient and stable transfection experiments. 33, 34 Colonies were stained with crystal violet after 14 days in selection medium.
One MOLT-4-derived clone, overexpressing VEGF, was used in subsequent studies and was cultured in RPMI 1640 in the presence of 500 g/ml of G418.
VEGF protein levels
Intracellular VEGF protein levels, and the amount secreted in the medium by MOLT-4 cells, was measured with a Quantikine immunoassay kit (R&D Systems) according to the manufacturer's instructions. aplidine did not interfere with the measurement of VEGF (absorbance of 300 pg/ml VEGF was 0.734 ± 0.008 without aplidine, and 0.710 ± 0.001 in the presence of 20 nM aplidine).
VEGF and VEGFR-1 mRNA analysis
VEGF and VEGFR-1 mRNA were measured by RNase protection using a commercially available kit (Becton Dickinson, Franklin Lakes, NJ, USA) or by Northern blotting analysis according to standard procedures. 35 
Electrophoretic mobility shift assay
Untreated or aplidine-treated cells (10 6 ) were lysed in chilled buffer containing 10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 0.8% Nonidet NP-40. Nuclei were pelleted, extracted for 1 h in extraction buffer (20 mM Hepes pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF) and cleared from debris by centrifugation at 12 000 g for 15 min. Ten g of nucleic extracts were incubated on ice for 1 h in 15 l of buffer containing 20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM Leukemia MgCl 2 , 0.1% NP40, 5% sucrose, 1 g poly(dIdC), and 1 ng of 32 P-end-labeled oligonucleotide, in the absence or presence of different aplidine concentrations.
The oligonucleotides utilized, HIF-1 (5Ј-TGCATACGTGGG CTCCAACAG-3Ј) and AP-1 (5Ј-AGGGGCAAAGTGAGTGAC CTGCTT-3Ј), have been synthetized from their recognition sequence present in the VEGF promoter. DNA-protein complexes were separated by electrophoresis through a 5% native polyacrylamide gel, dried and visualized by phosphoimager analysis (Storm, Amersham Biosciences, Milan, Italy). 
Measurement of VEGF half-life
VEGF mRNA half-life was determined by RNase protection. Total RNA from untreated or aplidine-treated (20 nM) MOLT-4 cells was extracted at 10, 20, 40, 60 and 120 min after the addition of 2.5 g/ml of actinomycin D (Sigma, St Louis, MO, USA). For each time-point, three different replicates were performed.
VEGF promoter activity
A 1005-bp long DNA fragment containing the promoter region of VEGF, subcloned 5Ј to the luciferase gene in the PGL2 basic vector (Promega), was used to analyze transcription control of this gene under varying treatment conditions. Cells were co-transfected by electroporation with 4 g of pGL2-derived plasmids containing the 5Ј flanking region of the VEGF gene and 0.05 g of pRL-SV40 used for internal normalization. After treatment with varying aplidine concentrations for 1 h, reporter gene activities were evaluated 24 h after using the Dual Luciferase system (Promega). Results are expressed as the percentage of the control luciferase activity normalized by the renilla activity value used as internal standard. The mean ± s.d. of three independent experiments is shown.
Evaluation of apoptosis
At different time intervals after drug washout, the cells were fixed in ethanol 70% and stored at 4°C. The fixed cells were washed in cold PBS and permeabilized with 0.25% Triton X-100 (Sigma) in PBS for 5 min on ice. After removing Triton X-100, the cells were incubated in 50 l of a solution containing Terminal-dUTP-Transferase and FITC-conjugated dUTP deoxynucleotides 1:1 in storage buffer (Roche Diagnostic,
Figure 3
Dose-dependent decrease in VEGF secretion induced by aplidine treatment of MOLT-4 cells. Cells were treated for 1 h with aplidine, washed and incubated in drug-free medium for a further 6 and 24 h. Milan, Italy) for 60-90 min at 37°C in the dark. After washing in PBS the cells were resuspended in PBS and analyzed by FacsCalibur instrument. At least 10 000 cells were evaluated for each sample.
Results
The human leukemic cell line MOLT-4 is sensitive to treatment with nanomolar concentrations of aplidine. The IC 50 (concentration inhibiting the growth by 50%) of the drug, evaluated after 72 h incubation in drug-free medium following 1 h treatment, is approximately 10 nM.
In a previous study aimed at evaluating early changes in gene expression in MOLT-4 cells after 1 h treatment with 10 nM of aplidine, we found that among different genes whose expression was modulated, a time-dependent reduction of the VEGF-R1 mRNA was observed. 12 This decrease was confirmed by PCR and subsequently by Western blotting analysis. 12 To study whether the changes in gene expression induced by aplidine could be extended to other members of the VEGF receptor and to ligands of VEGFR-1, we used the RNase protection assay with probes of different genes involved in angiogenesis including VEGF. The results ( Figure  2a) clearly show that aplidine, as previously found, induces a decrease in the expression of VEGFR-1, but more dramatically reduces the expression of VEGF mRNA which was not detectable at 6 and 24 h. VEGFR-2 is not expressed by MOLT-4 cells.
We therefore tested the effect of aplidine treatment on the amount of VEGF protein secreted in the medium (Figure 2b ). Untreated cells secrete approximately 1.6 pg of VEGF/ml/10 5 cells. After treatment with 20 nM aplidine, the levels of VEGF were below the detection limit already at the end of treatment and remained at these levels after 6 and 24 h of post-drug treatment incubation. Figure 3 shows the levels of VEGF secreted in the medium 55 in MOLT-4 cells treated for 1 h with different aplidine concentrations. A clear dose-dependent reduction of VEGF secretion was observed at the end of treatment. At concentrations close to the IC 50 the secretion of VEGF remained low 6 and 24 h after drug washout, while at lower concentrations the decrease in VEGF secretion was reversible. We focused on the mechanisms responsible for the aplidine-induced reduction of VEGF production in MOLT-4 cells, initially by checking whether a reduced transcription of the gene could account for this effect. In transient transfection experiments, we used a fragment of the human VEGF promoter containing the first 1000 bp 5Ј to the transcription starting site fused to the reporter luciferase gene. Cells were transfected by electroporation, treated for 1 h with different concentrations of aplidine and luciferase activity was determined 24 h after. At all the concentrations tested (all previously reported to induce a down-regulation of VEGF mRNA and protein) the promoter activity was substantially unaffected by aplidine (Figure 4a ). The fragment of the promoter we used contains the binding site for HIF-1, one of the most important regulator of VEGF transcription under hypoxic conditions, and for AP-1. By gel retardation assay we analyzed whether aplidine interfered with the binding of HIF-1 and AP-1 to their DNA consensus sequences. When nuclear extracts obtained from MOLT-4 cells were preincubated with different concentrations of aplidine (ranging from 1 nM to 100 M), no change in the binding of either HIF-1 or AP-1, even at the highest concentration was observed (Figure 4b and c) . Likewise, aplidine was unable to interfere with the binding of these two transcription factors to their consensus DNA sequences when extracts from cells treated with different concentrations of aplidine were used in gel retardation experiments (data not shown).
The levels of VEGF mRNA are not only controlled transcriptionally, but also post transcriptionally. We therefore analyzed whether aplidine was able to change the half-life of VEGF mRNA in MOLT-4 cells ( Figure 5 ). Analysis of VEGF mRNA levels in untreated or aplidine-treated MOLT-4 cells at 0, 20, 40, 60 and 120 min after the addition of actinomycin D showed that the drug, in the three independent experiments performed, does not induce a faster degradation of VEGF mRNA.
When we measured the intracellular VEGF protein levels, however, we found that concomitant with a reduction of VEGF secreted in the medium, a concentration-dependent accumulation of intracellular VEGF was observed at the end of 1 h of aplidine treatment ( Figure 6 ).
To test whether the aplidine-induced VEGFR-1 down-regulation was also observable in the absence of VEGF production, we performed additional experiments using normal endothelial cells, which do express VEGFR-1 but do not secrete VEGF. Figure 7 shows that treatment of these cells with aplidine did not result in significant inhibition of VEGF-R1 mRNA, even at 20 nM.
To analyze whether aplidine could exert its antiproliferative activity on MOLT-4 by blocking the autocrine VEGF-VEGFR-1 loop, we performed cell growth inhibition experiments in the presence of exogenous VEGF added in the medium. Ten ng/ml of VEGF added in the medium together with aplidine, and maintained in a drug-free medium incubation period, reduced the activity of the drug, particularly at low aplidine concentrations (Figure 8 ).
To study further the importance of VEGF secretion for the growth of MOLT-4 cells, we transfected these cells with VEGF cDNA either in sense or antisense orientation. Transfection of VEGF sense cDNA allowed us to recover different colonies
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Panel ( (with a percentage similar to that obtained after transfection with the empty vector), while the transfection of the antisense VEGF construct resulted in complete inhibition of colony formation. Transfection of the same DNA constructs in another human cancer cell line (A2780) not expressing VEGF receptors, did show formation of colonies with both constructs at comparable levels (data not shown).
One of the clones transfected with VEGF cDNA was used for subsequent experiments. The increased secretion of VEGF from this clone resulted in the protection from aplidine treatment. The drug, in fact, required more than two-fold higher concentrations to induce the same growth inhibition as in the parental MOLT-4 cells (Figure 9a ), and showed a decreased apoptotic effect, evaluated by flow cytometry after Tunel staining (Figure 9b ). The latter effect is particularly evident after 10 nM, where the percentage of apoptotic cells in parental MOLT-4 cells was approximately 90% which decreased to approximately 50% in the clone transfected with VEGF. Both parental and VEGF-transfected MOLT-4 cells grew in vitro at a similar rate, and the actual number of cells of untreated controls 48 h after treatment were 710 000 ± 53 000 and 761 000 ± 89 000 cells/ml respectively for parental and VEGF-transfected cells.
Discussion
In this present paper we show that VEGF acts as a growth factor in MOLT-4 cells and that aplidine, a new and promising anticancer agent currently in clinical trials, [6] [7] [8] [9] exerts its cytotoxic activity in these cells by interfering with the autocrine loop involving VEGF and its receptor, VEGFR-1.
MOLT-4 cells, in fact, not only secrete VEGF as almost all cancer cells do, but also express on their surface the VEGFR-1 receptor.
11, 36 The finding reported here that transfection with growth of MOLT-4 cells. 36, 37 A role for VEGF as a growth factor has been described for endothelial cells and only recently for certain cancer cells growing in vitro. [25] [26] [27] [28] [29] In normal endothelial cells, VEGF stimulates cell growth by inhibiting apoptosis, mainly through the activation of antiapoptotic proteins. 17, 30, 31 Even if not formally demonstrated, there is evidence, presented here and reported in the literature, 26, 31 suggesting that in certain cancer cells VEGF could also act as a growth factor by inducing antiapoptotic proteins and more generally by inhibiting apoptosis. The evidence that a MOLT-4-derived clone overproducing VEGF is less susceptible to aplidine treatment and is less prone to undergo apoptosis, is in line with this hypothesis. Indirectly, these results suggest that compounds able to block VEGF action in these systems should arrest all growth and induce apoptosis.
Aplidine, at least in MOLT-4 cells, appears to act by blocking VEGF secretion, a mechanism of action that has never been described before for an antileukemic or anticancer agent.
The mechanism by which aplidine inhibits VEGF secretion
Leukemia is at present unknown. It seems, however, that this is the primary effect of the drug which then presumably causes a cascade of events, including inhibition of new VEGF mRNA synthesis and down-regulation of VEGFR-1 receptor. That the decrease in the receptor levels is not a direct drug effect but rather a consequence of a block in VEGF secretion is also supported by the evidence that human endothelial cells growing in culture, not producing VEGF, do not show any decrease in VEGFR-1 levels after treatment with aplidine. Preliminary evidence suggests that aplidine blocks VEGF secretion with a certain degree of specificity being, in another leukemic cell line (NB4), able to block VEGF secretion (as observed in MOLT-4 cells) but not the secretion of other proteins such as TNF-alpha or MCP-1 (data not shown). The mechanism proposed here ( Figure 10 ), could represent one of the possible mechanisms by which aplidine exerts its anticancer activity, but it does not exclude the possibility that in other cancer cell types the drug could act with a different mechanism(s).
Finally, VEGF is an important mediator of angiogenesis,
Figure 10
Proposed scheme for the VEGF/VEGFR-1 autocrine loop and the way in which aplidine induces growth arrest and apoptosis.
being mitogenic for endothelial cells and causing angiogenic response in vivo. 24, 38 Recently, an important role for angiogenesis in patients with leukemia has been shown, [39] [40] [41] [42] [43] raising the possibility of a role of anti-angiogenic drugs in the treatment of these types of cancer. By blocking VEGF secretion, aplidine, apart from its ability to induce growth factor deprivation, could affect angiogenesis in hematopoietic malignancies. The levels of aplidine that reduced VEGF in our experiments in vitro are in the same range of the levels reached in plasma of treated patients. 44 Considering that aplidine has shown some activity in patients with lymphomas in the clinic 44 our finding may have important implications in explaining this activity. The potential for anti-angiogenic activity of aplidine, warrants further investigations.
